FIELD: medicine.
SUBSTANCE: present invention refers to medicine, particularly to cardiology and concerns atherosclerosis treatment. For this purpose effective amount of soluble CTLA4 is introduced.
EFFECT: method enables to block the inflammatory processes underlying pathological changes associated with atherosclerosis, due to binding CTLA4 and B7 molecules and prevented interaction with ligands.
18 cl, 21 tbl, 9 ex, 87 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF RHEUMATIC DISEASES BY USING SOLUBLE CTLA4 | 2001 |
|
RU2287340C2 |
| METHOD OF TREATING IL-1BETA-DEPENDENT DISEASES | 2007 |
|
RU2554747C9 |
| SOLUBLE MUTANT CTLA4 AND USES THEREOF | 2001 |
|
RU2283847C2 |
| SOLUBLE MUTANT CTLA4 MOLECULES | 1998 |
|
RU2235555C2 |
| METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLARTHRITIS BY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | 2016 |
|
RU2728710C2 |
| NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
| HUMANIZED ANTIBODIES TO CTLA4 | 2012 |
|
RU2629768C2 |
| COMPOSITIONS AND METHODS FOR TREATING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | 2004 |
|
RU2411042C2 |
| TREATING AUTOIMMUNE DISEASES WITH CD154 ANTIBODIES | 2015 |
|
RU2695443C2 |
| METHODS FOR INDUCING T-CELLULAR TOLERANCE FOR TISSUE OR ORGAN TRANSPLA - NT | 1995 |
|
RU2169009C2 |
